Editorial Views  |   May 2017
Malignant Hypercompliance
Author Notes
  • From the Department of Anesthesiology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin.
  • Accepted for publication January 10, 2017.
    Accepted for publication January 10, 2017.×
  • Corresponding article on page 774.
    Corresponding article on page 774.×
  • Address correspondence to Dr. Hogan: khogan@wisc.edu
Article Information
Editorial Views / Central and Peripheral Nervous Systems / Neuromuscular Diseases and Drugs / Pharmacology / Quality Improvement
Editorial Views   |   May 2017
Malignant Hypercompliance
Anesthesiology 5 2017, Vol.126, 759-762. doi:10.1097/ALN.0000000000001597
Anesthesiology 5 2017, Vol.126, 759-762. doi:10.1097/ALN.0000000000001597
AT the University of Wisconsin, Madison, Wisconsin, in the 1970s, a circulating nurse was designated to maintain a list of all malignant hyperthermia (MH) family surnames taped to the inside of the swinging doors to the operating suite to be cross-checked by everyone responsible for preoperatively evaluating a patient. Efforts to avoid trigger agents at all costs in those at heightened susceptibility by family history led to risky and often unpleasant alternative anesthetic regimens. Imagine, for example, induction and maintenance of anesthesia for an upper abdominal procedure in a difficult airway patient at risk for MH before introduction of fiber-optic laryngoscopy and nontrigger IV anesthetics. Lethality of the syndrome during the two decades that elapsed between its recognition and its suppression by dantrolene engendered waking nightmares in the care of probands who triggered in the absence of advanced warning.
First Page Preview
First page PDF preview
First page PDF preview ×
View Large